Peter Olupot-Olupot/Lancet Haematol
2 results
Incidence of clinically diagnosed infections in children with sickle cell anaemia treated with oral hydroxyurea in Angola, DR Congo, Kenya, and Uganda: a retrospective cohort study from the REACH trial.Williams, T. N.
Smart, L. R.
Tomlinson, G.
Santos, B.
Tshilolo, L.
Olupot-Olupot, P.
Aygun, B.
Stuber, S. E.
Lane, A.
Latham, T.
Ware, R. E.
Lancet Haematol, (2026). :
Hydroxyurea dose optimisation for children with sickle cell anaemia in sub-Saharan Africa (REACH): extended follow-up of a multicentre, open-label, phase 1/2 trial.Aygun, B.
Lane, A.
Smart, L. R.
Santos, B.
Tshilolo, L.
Williams, T. N.
Olupot-Olupot, P.
Stuber, S. E.
Tomlinson, G.
Latham, T.
Ware, R. E.
Reach Investigators
Lancet Haematol, (2024). 11:e425-e435